Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Fujii

Showing results (481-490 of 518) with videos related to

Pageof 52
Sort By:
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 11, 2026
Comparison of area under the concentration-time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point samplingAyako Suzuki, Hisato Fujihara, Fumihiro Yamaguchi, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 2, 2025
Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoringAyako Suzuki, Hisato Fujihara, Fumihiro Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket TrialMasataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, et al.
Pharmaceutical Research|October 21, 2024
Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian EstimationAyako Suzuki, Masaru Samura, Tomoyuki Ishigo, et al.
Plos One|December 2, 2015
Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by ChemoradiotherapyYosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi, et al.
The Journal of Pharmacy and Pharmacology|June 16, 2025
Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective studyTomoyuki Ishigo, Ayako Suzuki, Yuta Ibe, et al.
Esophagus : Official Journal of the Japan Esophageal Society|February 14, 2024
Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancerTomonori Yano, Yoshito Hayashi, Ryu Ishihara, et al.
Microbiology Spectrum|May 22, 2024
Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective studyTomoyuki Ishigo, Kazuaki Matsumoto, Hiroaki Yoshida, et al.
AJNR. American Journal of Neuroradiology|July 21, 2025
Digital FDG-PET detects <i>MYD88</i> mutation-driven glycolysis in primary central nervous system lymphomaMayu Sasaki, Yuri Teraoka, Ayumi Kato, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 24, 2025
Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patientsToshiaki Komatsu, Atsushi Tomizawa, Masaru Samura, et al.
Pageof 52

Showing results (481-490 of 518) with videos related to

Sort By:
Pageof 52
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 11, 2026
Comparison of area under the concentration-time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point samplingAyako Suzuki, Hisato Fujihara, Fumihiro Yamaguchi, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 2, 2025
Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoringAyako Suzuki, Hisato Fujihara, Fumihiro Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket TrialMasataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, et al.
Pharmaceutical Research|October 21, 2024
Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian EstimationAyako Suzuki, Masaru Samura, Tomoyuki Ishigo, et al.
Plos One|December 2, 2015
Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by ChemoradiotherapyYosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi, et al.
The Journal of Pharmacy and Pharmacology|June 16, 2025
Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective studyTomoyuki Ishigo, Ayako Suzuki, Yuta Ibe, et al.
Esophagus : Official Journal of the Japan Esophageal Society|February 14, 2024
Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancerTomonori Yano, Yoshito Hayashi, Ryu Ishihara, et al.
Microbiology Spectrum|May 22, 2024
Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective studyTomoyuki Ishigo, Kazuaki Matsumoto, Hiroaki Yoshida, et al.
AJNR. American Journal of Neuroradiology|July 21, 2025
Digital FDG-PET detects <i>MYD88</i> mutation-driven glycolysis in primary central nervous system lymphomaMayu Sasaki, Yuri Teraoka, Ayumi Kato, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 24, 2025
Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patientsToshiaki Komatsu, Atsushi Tomizawa, Masaru Samura, et al.
Pageof 52